Iovance Biotherapeutics (IOVA) Competitors $5.91 +0.15 (+2.60%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends IOVA vs. RVMD, LNTH, BBIO, BPMC, LEGN, ELAN, CYTK, NUVL, GRFS, and TGTXShould you be buying Iovance Biotherapeutics stock or one of its competitors? The main competitors of Iovance Biotherapeutics include Revolution Medicines (RVMD), Lantheus (LNTH), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Nuvalent (NUVL), Grifols (GRFS), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. Iovance Biotherapeutics vs. Revolution Medicines Lantheus BridgeBio Pharma Blueprint Medicines Legend Biotech Elanco Animal Health Cytokinetics Nuvalent Grifols TG Therapeutics Revolution Medicines (NASDAQ:RVMD) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, community ranking, analyst recommendations, dividends, media sentiment, institutional ownership and profitability. Does the media favor RVMD or IOVA? In the previous week, Revolution Medicines and Revolution Medicines both had 6 articles in the media. Revolution Medicines' average media sentiment score of 0.28 beat Iovance Biotherapeutics' score of -0.04 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Iovance Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts prefer RVMD or IOVA? Revolution Medicines currently has a consensus target price of $66.25, suggesting a potential upside of 64.43%. Iovance Biotherapeutics has a consensus target price of $23.00, suggesting a potential upside of 289.17%. Given Iovance Biotherapeutics' higher probable upside, analysts clearly believe Iovance Biotherapeutics is more favorable than Revolution Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revolution Medicines 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08Iovance Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 Does the MarketBeat Community favor RVMD or IOVA? Iovance Biotherapeutics received 474 more outperform votes than Revolution Medicines when rated by MarketBeat users. However, 75.83% of users gave Revolution Medicines an outperform vote while only 74.44% of users gave Iovance Biotherapeutics an outperform vote. CompanyUnderperformOutperformRevolution MedicinesOutperform Votes9175.83% Underperform Votes2924.17% Iovance BiotherapeuticsOutperform Votes56574.44% Underperform Votes19425.56% Which has preferable earnings & valuation, RVMD or IOVA? Revolution Medicines has higher earnings, but lower revenue than Iovance Biotherapeutics. Revolution Medicines is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRevolution Medicines$742K9,134.16-$436.37M-$3.59-11.22Iovance Biotherapeutics$1.19M1,513.66-$444.04M-$1.49-3.97 Which has more risk and volatility, RVMD or IOVA? Revolution Medicines has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Do institutionals & insiders have more ownership in RVMD or IOVA? 94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are held by institutional investors. 8.0% of Revolution Medicines shares are held by company insiders. Comparatively, 12.1% of Iovance Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is RVMD or IOVA more profitable? Revolution Medicines has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -451.25%. Revolution Medicines' return on equity of -33.67% beat Iovance Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Revolution MedicinesN/A -33.67% -30.08% Iovance Biotherapeutics -451.25%-58.43%-45.48% SummaryRevolution Medicines beats Iovance Biotherapeutics on 12 of the 18 factors compared between the two stocks. Get Iovance Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IOVA vs. The Competition Export to ExcelMetricIovance BiotherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.80B$2.96B$5.36B$9.09BDividend YieldN/A1.94%5.13%4.03%P/E Ratio-3.9745.5689.4717.33Price / Sales1,513.66358.911,253.32134.80Price / CashN/A192.9043.7535.97Price / Book2.593.975.324.80Net Income-$444.04M-$41.02M$122.60M$224.91M7 Day Performance-7.66%8.62%0.87%1.90%1 Month Performance-18.60%10.70%4.80%5.08%1 Year Performance-25.57%5.54%27.90%21.15% Iovance Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IOVAIovance Biotherapeutics4.1591 of 5 stars$5.91+2.6%$23.00+289.2%-26.5%$1.95B$1.19M0.00500News CoverageGap UpRVMDRevolution Medicines4.4701 of 5 stars$42.78+2.4%$66.25+54.9%+50.2%$7.20B$742,000.00-11.92250News CoveragePositive NewsLNTHLantheus4.5448 of 5 stars$94.38-1.6%$131.86+39.7%+65.5%$6.56B$1.50B15.70700Analyst ForecastShort Interest ↑BBIOBridgeBio Pharma4.0937 of 5 stars$33.79+16.2%$48.08+42.3%-8.5%$6.39B$217.77M-14.02400Short Interest ↑High Trading VolumeBPMCBlueprint Medicines1.6713 of 5 stars$100.16+14.6%$122.72+22.5%+38.6%$6.36B$434.42M-47.47640Analyst ForecastInsider TradeShort Interest ↑Analyst RevisionGap UpLEGNLegend Biotech2.5097 of 5 stars$31.93-5.0%$80.62+152.5%-45.5%$5.83B$520.18M-33.611,800Short Interest ↓News CoverageELANElanco Animal Health4.4179 of 5 stars$11.56+1.1%$16.43+42.1%-18.8%$5.71B$4.45B28.909,800CYTKCytokinetics4.3227 of 5 stars$46.51-0.2%$83.64+79.8%-46.6%$5.49B$7.53M-8.64250Analyst ForecastNUVLNuvalent1.797 of 5 stars$73.03-4.7%$112.36+53.9%+2.7%$5.19BN/A-21.0540Analyst ForecastInsider TradeNews CoverageGRFSGrifols2.0517 of 5 stars$7.25-0.5%N/A+7.2%$4.98B$7.01B5.9426,300Positive NewsGap DownTGTXTG Therapeutics4.4939 of 5 stars$27.94-3.3%$40.67+45.5%+93.1%$4.35B$264.79M-279.37290Analyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies Revolution Medicines Competitors Lantheus Competitors BridgeBio Pharma Competitors Blueprint Medicines Competitors Legend Biotech Competitors Elanco Animal Health Competitors Cytokinetics Competitors Nuvalent Competitors Grifols Competitors TG Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IOVA) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
